These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 28153708)

  • 1. Steroidogenic acute regulatory protein (StAR) overexpression attenuates HFD-induced hepatic steatosis and insulin resistance.
    Qiu Y; Sui X; Zhan Y; Xu C; Li X; Ning Y; Zhi X; Yin L
    Biochim Biophys Acta Mol Basis Dis; 2017 Apr; 1863(4):978-990. PubMed ID: 28153708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance.
    Kim HY; Park SY; Lee MH; Rho JH; Oh YJ; Jung HU; Yoo SH; Jeong NY; Lee HJ; Suh S; Seo SY; Cheong J; Jeong JS; Yoo YH
    J Hepatol; 2015 Aug; 63(2):477-85. PubMed ID: 25646886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
    Fu D; Cui H; Zhang Y
    Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FBXW7 suppresses HMGB1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease.
    Zhang C; Chen F; Feng L; Shan Q; Zheng GH; Wang YJ; Lu J; Fan SH; Sun CH; Wu DM; Li MQ; Hu B; Wang QQ; Zhang ZF; Zheng YL
    Mol Med; 2019 Jun; 25(1):29. PubMed ID: 31215394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
    Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
    J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor.
    Liu M; Zhang G; Wu S; Song M; Wang J; Cai W; Mi S; Liu C
    J Ethnopharmacol; 2020 Jun; 255():112776. PubMed ID: 32205261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of glycosylphosphatidylinositol-specific phospholipase D on hepatic diacylglycerol accumulation, steatosis, and insulin resistance in diet-induced obesity.
    Masuda S; Fujishima Y; Maeda N; Tsugawa-Shimizu Y; Nakamura Y; Tanaka Y; Obata Y; Fukuda S; Nagao H; Kita S; Nishizawa H; Shimomura I
    Am J Physiol Endocrinol Metab; 2019 Feb; 316(2):E239-E250. PubMed ID: 30457913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
    Zhuge B; Li G
    Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice.
    Kant R; Lu CK; Nguyen HM; Hsiao HH; Chen CJ; Hsiao HP; Lin KJ; Fang CC; Yen CH
    Biomed Pharmacother; 2020 Sep; 129():110348. PubMed ID: 32554245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease.
    Xu M; Zheng XM; Jiang F; Qiu WQ
    J Cell Biochem; 2018 Jul; 119(7):5864-5874. PubMed ID: 29575055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
    Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
    J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
    Xiao Z; Chu Y; Qin W
    Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. iPLA2β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling.
    Deng X; Wang J; Jiao L; Utaipan T; Tuma-Kellner S; Schmitz G; Liebisch G; Stremmel W; Chamulitrat W
    Biochim Biophys Acta; 2016 May; 1861(5):449-61. PubMed ID: 26873633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
    Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
    Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARM1 deletion restrains NAFLD induced by high fat diet (HFD) through reducing inflammation, oxidative stress and lipid accumulation.
    Pan ZG; An XS
    Biochem Biophys Res Commun; 2018 Apr; 498(3):416-423. PubMed ID: 29454967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular cystathionine γ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor.
    Xu W; Cui C; Cui C; Chen Z; Zhang H; Cui Q; Xu G; Fan J; Han Y; Tang L; Targher G; Byrne CD; Zheng MH; Yang L; Cai J; Geng B
    Hepatology; 2022 Dec; 76(6):1794-1810. PubMed ID: 35586979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatoprotective effect of Typhaneoside on non-alcoholic fatty liver disease via farnesoid X receptor in vivo and in vitro.
    Zheng Y; Zhao J; Miao D; Xu T; Wang L; Liu C; Gao Y; Yu L; Shen C
    Biomed Pharmacother; 2023 Aug; 164():114957. PubMed ID: 37295248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroidogenic Acute Regulatory Protein (StAR) Overexpression Reduces Inflammation and Insulin Resistance in Obese Mice.
    Qiu Y; Sui X; Cao S; Li X; Ning Y; Wang S; Yin L; Zhi X
    J Cell Biochem; 2017 Nov; 118(11):3932-3942. PubMed ID: 28402022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.